resolvin-d2 and Pneumonia

resolvin-d2 has been researched along with Pneumonia* in 3 studies

Other Studies

3 other study(ies) available for resolvin-d2 and Pneumonia

ArticleYear
Eosinophil Phenotypes Are Functionally Regulated by Resolvin D2 during Allergic Lung Inflammation.
    American journal of respiratory cell and molecular biology, 2023, Volume: 69, Issue:6

    Eosinophils (Eos) reside in multiple organs during homeostasis and respond rapidly to an inflammatory challenge. Although Eos share chemical staining properties, they also demonstrate phenotypic and functional plasticity that is not fully understood. Here, we used a murine model of allergic lung inflammation to characterize Eos subsets and determine their spatiotemporal and functional regulation during inflammation and its resolution in response to resolvin D2 (RvD2), a potent specialized proresolving mediator. Two Eos subsets were identified by CD101 expression with distinct anatomic localization and transcriptional signatures at baseline and during inflammation. CD101

    Topics: Alveolitis, Extrinsic Allergic; Animals; Bronchoalveolar Lavage Fluid; Eosinophils; Inflammation; Mice; Phenotype; Pneumonia; Pulmonary Eosinophilia

2023
Back to the Eosinophil: Resolvin Spatiotemporal Regulation.
    American journal of respiratory cell and molecular biology, 2023, Volume: 69, Issue:6

    Topics: Alveolitis, Extrinsic Allergic; Docosahexaenoic Acids; Eosinophils; Fatty Acids; Humans; Phenotype; Pneumonia; Pulmonary Eosinophilia

2023
Resolvin D2 promotes host defense in a 2 - hit model of sepsis with secondary lung infection.
    Prostaglandins & other lipid mediators, 2022, Volume: 159

    In the development of sepsis, there is early, massive inflammation which can lead to multiple organ failure. Later there is an immunosuppressed phase where the host is susceptible to secondary infections or is unable to clear existing infection. Specialized Pro-resolving Mediators (SPMs) are endogenously produced lipids which resolve infection by decreasing bacteria load and reducing systemic inflammatory response. There has been little work studying if SPMs given late, can promote host defense. We examined if an SPM, Resolvin D2 (RvD2) could promote host defense in a 2-hit mouse model of cecal ligation and puncture (CLP) sepsis and secondary Pseudomonas aeruginosa lung infection. RvD2 given 48 h after mild CLP (1st hit), increased gene expression of Toll-like receptor-2 (TLR-2) and alveolar macrophage/monocyte phagocytic ability compared to CLP mice given saline vehicle. In this model, RvD2 did not affect plasma IL-6 or IL-10. These effects induced by RvD2, lowered lung bacterial load and decreased mortality after the secondary infection of Pseudomonas aeruginosa (2nd hit). Splenic T-cell numbers were also increased in RvD2 treated mice compared to saline vehicle treated animals. The results suggest that RvD2 promoted mechanisms of host defense in a 2-hit model sepsis and secondary lung infection.

    Topics: Animals; Coinfection; Cytokines; Disease Models, Animal; Docosahexaenoic Acids; Lung; Mice; Pneumonia; Pseudomonas Infections; Sepsis

2022